XML 54 R40.htm IDEA: XBRL DOCUMENT
v3.19.1

ORGANIZATION AND BASIS OF PRESENTATION (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Subsidiaries |
| (a) | As of December 31, 2018, subsidiaries of the Company and its consolidated variable interest entities included the following entities:
Entities |  | Date of establishment/acquisition |  | Place of establishment |  | Percentage of ownership by the Company |  |  | Principal activities
Subsidiaries |  |  |  |  |  |  |  |  |
Ascendium Group Limited (“Ascendium”) |  | September 10, 2007 |  | British Virgin Islands (“BVI”) |  | 100 | % |  | Investment holding
Concord Medical Investment Management Ltd. |  | October 28, 2016 |  | BVI |  | 100 | % |  | Investment holding
Our Medical Services Limited (“OMS”) |  | August 22, 1996 |  | BVI |  | 100 | % |  | Investment holding
Medstar Overseas Ltd. (“Medstar Overseas”) |  | September 22, 2011 |  | BVI |  | 100 | % |  | Investment holding
Cyber Medical Networks Limited (“Cyber”) |  | May 26, 2006 |  | Hong Kong |  | 100 | % |  | Investment holding
China Medical Services Holdings Limited (“CMS Holdings”) |  | July 18, 2008 |  | Hong Kong |  | 100 | % |  | Investment holding
King Cheers Holdings Limited (“King Cheers”) |  | May 18, 2001 |  | Hong Kong |  | 100 | % |  | Investment holding
Shenzhen Aohua Medical Technology Development Co., Ltd. (“Aohua Technology ”) |  | February 21, 2008 |  | PRC |  | 60 | % |  | Leasing of medical equipment and provision of management services
Medstar (Shanghai) Leasing Co., Ltd. (“Shanghai Medstar”) ** |  | March 21, 2003 |  | PRC |  | 100 | % |  | Leasing of medical equipment and provision of management services
Beijing MeizhongJiahe Hospital Management Co., Ltd. (“MHM”) * |  | July 23, 2008 |  | PRC |  | 60 | % |  | Provision of management services
Beijing Yundu Internet Technology Co., Ltd. (“Yundu”) |  | July 26, 2007 |  | PRC |  | 60 | % |  | Provision of management services
Tianjin Concord Medical Technology Limited (“Tianjin Concord Medical”) |  | April 22, 2010 |  | PRC |  | 100 | % |  | Leasing of medical equipment and provision of management services
Guangzhou Jinkangshenyou Investment Co., Ltd. (“JKSY”) |  | August 12, 2010 |  | PRC |  | 100 | % |  | Leasing of medical equipment
Guangzhou Concord Cancer Center (“Guangzhou Concord Cancer Hospital”) |  | June 29, 2011 |  | PRC |  | 48 | % |  | Group’s medical treatment and service business
CCM (Hong Kong) Medical Investments Limited (“CCM (HK)”) |  | June 03, 2013 |  | Hong Kong |  | 85.71 | % |  | Investment holding
Entities |  | Date of establishment/acquisition |  | Place of establishment |  | Percentage of ownership by the Company |  |  | Principal activities
Shenzhen Concord Medical Investment Limited (“SZ CMS”) |  | January 10, 2014 |  | PRC |  | 60 | % |  | Investment holding
Shanghai Concord Cancer Center Co., Ltd (“SHC”) |  | March 17, 2014 |  | PRC |  | 60.26 | % |  | Group’s medical treatment and service business
Global Medical Imaging (HongKong) Ltd. (“GMI”) |  | May 26, 2014 |  | Hong Kong |  | 100 | % |  | Investment holding
Datong Meizhong Jiahe Cancer Center (“DTMZ”) |  | October 23, 2014 |  | PRC |  | 60 | % |  | Group’s medical treatment and service business
Wuxi Concord Medical Development Ltd. ("Wuxi Concord”) |  | December 29, 2015 |  | PRC |  | 100 | % |  | Group’s medical treatment and service business
Concord Hospital Management Group Ltd. (“CHMG”) |  | July 7, 2015 |  | Hong Kong |  | 100 | % |  | Group’s medical treatment and service business
Beijing Concord Medical Technology Ltd.(“BJCMT”)** |  | January 4, 2016 |  | PRC |  | 100 | % |  | Provision of management services
Shanghai Taifeng Medical Technology Ltd (“Taifeng”) ** |  | March 30, 2016 |  | PRC |  | 60 | % |  | Group’s medical treatment and service business
Taizhou Concord Leasing Co., Ltd.** |  | April 20, 2016 |  | PRC |  | 100 | % |  | Group’s medical treatment and service business
Guofu Huimei (Tianjin) Investment Management Partnership Firm (LP) (“Guofu Huimei”) (note 4) |  | October 8, 2018 |  | PRC |  | 100 | % |  | Investment holding
Beijing Century Friendship Science & Technology Development Co., Ltd (“Beijing Century Friendship”) (note 4) |  | October 8, 2018 |  | PRC |  | 60 | % |  | Group’s medical treatment and service business
Beijing Proton Medical Center Co., Ltd (“BPMC”) (note 4) |  | October 8, 2018 |  | PRC |  | 58 | % |  | Group’s medical treatment and service business
Shanghai Meizhong Jiahe Cancer Center Co., Ltd. (“CMCC”) (note 4) |  | October 8, 2018 |  | PRC |  | 55.42 | % |  | Group’s medical treatment and service business
VIE |  |  |  |  |  |  |  |  |
ZR ConcordHealthcare Investment Fund SP (“SP”) |  | November 2016 |  | Cayman Islands |  | 25 | % |  | Investment holding
Subsidiaries of VIE |  |  |  |  |  |  |  |  |
US Proton Therapy Holdings Limited (“Proton BVI”) |  | May 16, 2011 |  | BVI |  | 25 | % |  | Investment holding
US Proton Therapy Holdings Limited (“US Proton”) |  | June 29, 2011 |  | United States of America |  | 25 | % |  | Investment holding
Concord Medical Services (International) Pte. Ltd. (“China Medstar”) (formerly known as China Medstar Pte. Limited) |  | August 8, 2003 |  | Singapore |  | 25 | % |  | Investment holding
Concord Healthcare Singapore Pte. Ltd. (“CHS”) |  | April 1, 2015 |  | Singapore |  | 25 | % |  | Group’s medical treatment and service business
* On August 27, 2015, the Group changed the name of CMS Hospital Management Co., Ltd. (“CHM”) to Beijing MeizhongJiahe Hospital Management Co., Ltd. (“MHM”), providing management service to the Group’s existing network.
Schedule of financial information | The following tables represent the financial information of the VIE and its subsidiaries as of December 31, 2017 and 2018 and for the years ended December 31, 2017 and 2018 before eliminating the intercompany balances and transactions between the VIE and its subsidiaries and other entities within the Group:
|  | As at December 31, |  |  | As at December 31, |
|  | 2017 |  |  | 2018 |  |  | 2018 |
|  | RMB |  |  | RMB |  |  | US$ |
ASSETS |  |  |  |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |  |  |  |
Cash |  |  | 13,161 |  |  |  | 15,935 |  |  |  | 2,318 |
Restricted cash, current portion |  |  | 42 |  |  |  | - |  |  |  | - |
Accounts receivable (net of allowance of RMB 73 (US$ 11 ) as of December 31, 2018) |  |  | 3,985 |  |  |  | 4,494 |  |  |  | 654 |
Inventories |  |  | 1,399 |  |  |  | 1,946 |  |  |  | 283 |
Prepayments and other current assets |  |  | 1,988 |  |  |  | 1,986 |  |  |  | 289 |
Amount due from inter-companies* |  |  | - |  |  |  | 80,523 |  |  |  | 11,711 |
Total current assets |  |  | 20,575 |  |  |  | 104,884 |  |  |  | 15,255 |
Non-current assets: |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  |  | 279,240 |  |  |  | 281,395 |  |  |  | 40,927 |
Intangible assets, net |  |  | 202 |  |  |  | 100 |  |  |  | 15 |
Deposits for non-current assets |  |  | 172 |  |  |  | - |  |  |  | - |
Long-term investments |  |  | 195,040 |  |  |  | 31,496 |  |  |  | 4,581 |
Other non-current assets |  |  | 481 |  |  |  | 464 |  |  |  | 67 |
Total non-current assets |  |  | 475,135 |  |  |  | 313,455 |  |  |  | 45,590 |
Total assets |  |  | 495,710 |  |  |  | 418,339 |  |  |  | 60,845 |
|  | As at December 31, |  |  | As at December 31, |
|  | 2017 |  |  | 2018 |  |  | 2018 |
|  | RMB |  |  | RMB |  |  | US$ |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  |  | 1,978 |  |  |  | 462 |  |  |  | 67 |
Accrued expenses and other liabilities |  |  | 21,321 |  |  |  | 42,681 |  |  |  | 6,208 |
Income tax payable |  |  | - |  |  |  | 2,870 |  |  |  | 417 |
Amount due to inter-companies* |  |  | 54,563 |  |  |  | - |  |  |  | - |
Total current liabilities |  |  | 77,862 |  |  |  | 46,013 |  |  |  | 6,692 |
Non-current liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liabilities |  |  | 8,316 |  |  |  | - |  |  |  | - |
Accrued unrecognized tax benefits & surcharge, non current portion |  |  | - |  |  |  | 20,208 |  |  |  | 2,939 |
Mandatorily redeemable noncontrolling interests |  |  | 396,281 |  |  |  | 434,216 |  |  |  | 63,154 |
Total non-current liabilities |  |  | 404,597 |  |  |  | 454,424 |  |  |  | 66,093 |
Total liabilities |  |  | 482,459 |  |  |  | 500,437 |  |  |  | 72,785 |
* Amount due from/to inter-companies represented receivable/payable balances of VIE and its subsidiaries due from/to other subsidiaries within the Group.
|  | As at December 31, |  |  | As at December 31, |
|  | 2017 |  |  | 2018 |  |  | 2018 |
|  | RMB |  |  | RMB |  |  | US$ |
Net revenues |  |  | 28,673 |  |  |  | 41,350 |  |  |  | 6,014 |
Net loss |  |  | (141,188 | ) |  |  | (95,788 | ) |  |  | (13,931 | )
|  | As at December 31, |  |  | As at December 31, |
|  | 2017 |  |  | 2018 |  |  | 2018 |
|  | RMB |  |  | RMB |  |  | US$ |
Net cash used in operating activities |  |  | (54,113 | ) |  |  | (260,884 | ) |  |  | (37,944 | )
Net cash (used in) generated from investing activities |  |  | (5,582 | ) |  |  | 221,130 |  |  |  | 32,162 |
Net cash generated from financing activities |  |  | 56,787 |  |  |  | 41,886 |  |  |  | 6,092 |
Exchange rate effect on cash, net |  |  | 748 |  |  |  | 600 |  |  |  | 87 |
(Decrease) increase in cash and cash equivalents |  |  | (2,160 | ) |  |  | 2,732 |  |  |  | 397 |

X
- Definition Schedule Of Subsidiaries And Principal Activities [Table Text Block] + References No definition available. + Details
Name: | ccm_ScheduleOfSubsidiariesAndPrincipalActivitiesTableTextBlock
Namespace Prefix: | ccm_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -URI http://asc.fasb.org/extlink&oid=108788376&loc=SL6759159-111685 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=108788376&loc=d3e5747-111685 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=108788376&loc=SL6228884-111685 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=108788376&loc=d3e5710-111685 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=108788376&loc=d3e5728-111685 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration